Drug Trial Radar · NCT06396026
A Study of Efficacy and Safety of TLL-018 in CSU Participants
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
440
Actual
Start
Mar 27, 2024
Primary completion
Oct 23, 2025
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) With Inadequate Controll to Second Generation H1-antihistamines.
Conditions
- Chronic Spontaneous Urticaria
Interventions
TLL-018 tabletsDrug
Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks
Placebo tabletsDrug
Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in UAS7 at Week 12Time frame: 12 weeks
- Change from baseline in ISS7 at Week 12Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.